Indication and Limitation of Use

Vectibix® is indicated for the treatment of patients with wild-type KRAS (exon 2 in codons 12 or 13) metastatic colorectal cancer (mCRC) as determined by an FDA-approved test for this use: as first-line therapy in combination… read more

Vectibix® is indicated for the treatment of patients with wild-type KRAS (exon 2 in codons 12 or 13)… read more

Vectibix® is indicated for the treatment of patients with wild-type KRAS (exon 2 in codons 12 or 13) metastatic colorectal cancer (mCRC) as determined by an FDA-approved test… read more

Vectibix® is indicated for the treatment of patients with wild-type KRAS (exon 2 in codons 12 or 13) metastatic colorectal cancer (mCRC) as determined by an FDA-approved test for this use: as first-line therapy in combination with FOLFOX, as monotherapy following disease progression after prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy.

Vectibix® is not indicated for the treatment of patients with RAS-mutant mCRC or for whom RAS mutation status is unknown.

×
×

You are now leaving Vectibix.com

Please know that the sponsors of this site are not responsible for content on the site you are about to enter.

Cancel
Continue

How to prepare and administer Vectibix® treatment

Vectibix® preparation1

4 steps to preparing Vectibix®

Please note: Do not administer Vectibix® as an intravenous push or bolus.1
Follow these steps to prepare the solution for infusion, using aseptic technique:

  1. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Although Vectibix® should be colorless, the solution may contain a small amount of visible translucent-to-white, amorphous, proteinaceous panitumumab particulates, which will be removed by filtration. Do not shake. Do not administer Vectibix® if discoloration is observed.1
  2. Withdraw the necessary amount of Vectibix® for a dose of 6 mg/kg.1
  3. Dilute to a total volume of 100 mL with 0.9% sodium chloride injection, USP. Final concentration should not exceed 10 mg/mL. Doses of higher than 1,000 mg should be diluted to 150 mL with 0.9% sodium chloride injection, USP.1
  4. Mix diluted solution by gentle inversion. DO NOT SHAKE.1
Dosing Examples
Patient weight 76 kg (167.5 lb)
Dose 6 mg/kg
Dose calculation 6 mg/kg x 76 kg =
456 mg (22.8 mL)
400 mg
400mg
(20 mL vial size)
100 mg
100mg
(20 mL vial size)

Vectibix® administration1

4 steps to administering Vectibix®

  1. Administer using a low-protein-binding 0.2 µm in-line filter.1
  2. Vectibix® must be administered via infusion pump.1
    • Flush line before and after Vectibix® administration with 0.9% sodium chloride injection, USP, to avoid mixing with other drug products or intravenous solutions. Do not mix Vectibix® with, or administer as an infusion with, other medicinal products. Do not add other medications to solutions containing panitumumab.1
    • Infuse doses of 1000 mg or lower over 60 minutes through a peripheral intravenous line or indwelling intravenous catheter. If the first infusion is tolerated, administer subsequent infusions over 30 to 60 minutes. Administer doses higher than 1000 mg over 90 minutes.1
  3. Use the diluted infusion solution of Vectibix® within 6 hours of preparation if stored at room temperature, or within 24 hours of dilution stored at 2° to 8°C (36° to 46°F). DO NOT FREEZE.1
  4. Discard any unused portion remaining in the vial.1
Site Map
×